Uveoretinal Adverse Effects Presented during Systemic Anticancer Chemotherapy: a 10-Year Single Center Experience
- Author:
Ah Ran CHO
1
;
Young Hee YOON
;
June Gone KIM
;
Yoon Jeon KIM
;
Joo Yong LEE
Author Information
- Publication Type:Original Article
- Keywords: Chemotherapy; Cancer Chemotherapy Agents; Targeted Molecular Therapy; Drug Toxicity; Uveitis
- MeSH: Antineoplastic Agents; Breast Neoplasms; Cisplatin; Cytarabine; Daunorubicin; Diagnosis; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasm Metastasis; Retrospective Studies; Tamoxifen; Toremifene; Uveitis; Uveitis, Anterior; Visual Acuity
- From:Journal of Korean Medical Science 2018;33(7):e55-
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: The present study describes our 10-year experience with uveoretinal adverse events that manifest because of chemotherapy. METHODS: A retrospective chart review was performed for all patients who presented to the ophthalmologic department while undergoing systemic chemotherapy between July 2005 and June 2015. RESULTS: A total of 55 patients (mean age, 51.2 years, 38 women [69.1%]) suspected of having uveoretinal disease owing to the use of chemotherapeutic agents alone were enrolled. Breast cancer was the predominant disease (36.4%); noninfectious anterior uveitis (21.8%) was the most common condition. Bilateral involvement was observed in 16 patients (29.1%). Although cisplatin (21.8%) was the most commonly used drug, daunorubicin, cytarabine, tamoxifen, toremifene, and imatinib were also frequently used. The median duration until ophthalmologic diagnosis was 208.5 days (range, 19–5,945 days). The proportion of patients with final visual acuity (VA) < 20/40 Snellen VA (0.5 decimal VA) was 32.7%. However, no relationship was observed between final VA < 20/40 and age, sex, therapeutic agents, and metastasis. CONCLUSION: Uveoretinal complications were mostly mild to moderate and exhibited a favorable response to conservative therapy. A considerable number of patients exhibited significant irreversible loss of vision after cessation of the causative chemotherapeutic agent. Ophthalmological monitoring is required during chemotherapy.
